Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNP-2198 in Asymptomatic Helicobacter Pylori Infection
NCT06076681Phase 2Completed
- Sponsor
- TenNor Therapeutics
- Start
- Sep 2021
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rifasutenizol in Helicobacter pylori infection (4 arms), sponsored by TenNor Therapeutics. Primary endpoint: The Eradication Rate of Helicobacter Pylori Infection. Started Sep 2021; status: completed.
02
Drugs
rifasutenizol
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT06076681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06076681.